Clinical Trial Update: A Study of TG103 Injection in Non-diabetic Overweight or Obesity [Phase 3]

View source ↗

Summary

Phase 3 study of TG103 Injection in non-diabetic individuals with overweight or obesity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• TG103 Injection

Snippet

Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Conditions: Overweight or Obesity | Phase 3 | Status: COMPLETED